CD8 expression
|
Prostate Cancer
|
CD8 expression
|
Prostate Cancer
|
atezolizumab + enzalutamide capsule Sensitive: B - Late Trials
|
atezolizumab + enzalutamide capsule Sensitive: B - Late Trials
|
CD8 expression
|
Melanoma
|
CD8 expression
|
Melanoma
|
pembrolizumab Sensitive: C2 – Inclusion Criteria
|
pembrolizumab Sensitive: C2 – Inclusion Criteria
|
CD8 expression
|
Urothelial Cancer
|
CD8 expression
|
Urothelial Cancer
|
PF-06801591 Sensitive: C3 – Early Trials
|
PF-06801591 Sensitive: C3 – Early Trials
|
CD8 expression
|
Melanoma
|
CD8 expression
|
Melanoma
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
CD8 expression
|
Melanoma
|
CD8 expression
|
Melanoma
|
ipilimumab Sensitive: C3 – Early Trials
|
ipilimumab Sensitive: C3 – Early Trials
|
CD8 expression
|
RCC
|
CD8 expression
|
RCC
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
CD8 expression
|
Solid Tumor
|
CD8 expression
|
Solid Tumor
|
TAB004 Sensitive: C3 – Early Trials
|
TAB004 Sensitive: C3 – Early Trials
|